The Q4 2016 earnings report for mid cap solar stock First Solar, Inc (NASDAQ: FSLR) is scheduled for after the market closes onTuesday (February 21st). First Solar had been in our SmallCap Network Elite Opportunity (SCN EO) portfolio back in 2014as we felt the stock to be a best of breed stock in the solar space, offered more upside based on current fundamentals and had a better balance sheet than its solar peers. Our SCN EO newsletter pointed out in March 2014:
It took years for fuel cell to get hot again after being a dead trade for what seemed like forever. 3D printing is another in the same category and even solar was a losing proposition for investors for a long time. However, after years and years of hype and promise, we believe now is the time for solar. However, it doesn’t mean we all should just run out and snap up every solar idea out there because it’s important to remember, the solar space, just like fuel cell, biotech and 3D printing, is littered with weak companies and dead technologies.
Top Biotech Stocks To Watch Right Now: Alnylam Pharmaceuticals Inc.(ALNY)
- [By Keith Speights]
I wrote three months ago that I viewed Alnylam Pharmaceuticals (NASDAQ:ALNY) stock as a pretty good pick — but with a couple of qualifications. First, I didn’t think that the biotech would generate returns in 2018 nearly as great as it did last year. Second, I thought that there were even better stocks to buy than Alnylam.
- [By Sean Williams, Chuck Saletta, and Brian Feroldi]
So, which biotech stocks should you consider buying in June? That’s a question we posed to three of our healthcare-focused investors. Interestingly enough, mid-cap biotech stocks are the clear flavor of the month. If biotech is on your radar in June, our investors suggest you consider Ionis Pharmaceuticals (NASDAQ:IONS), Spark Therapeutics (NASDAQ:ONCE), and Alnylam Pharmaceuticals (NASDAQ:ALNY).
- [By Shane Hupp]
Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
BidaskClub lowered shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) from a strong-buy rating to a buy rating in a research report released on Monday.
- [By Max Byerly]
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) EPS for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.06. The business had revenue of $21.90 million during the quarter, compared to analysts’ expectations of $35.23 million. Alnylam Pharmaceuticals had a negative return on equity of 36.81% and a negative net margin of 565.20%. The business’s quarterly revenue was up 15.3% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.25) earnings per share. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -6.7 earnings per share for the current fiscal year.
Top Biotech Stocks To Watch Right Now: Amgen Inc.(AMGN)
- [By Logan Wallace]
Intact Investment Management Inc. grew its holdings in Amgen (NASDAQ:AMGN) by 2,737.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,400 shares of the medical research company’s stock after purchasing an additional 43,800 shares during the period. Intact Investment Management Inc.’s holdings in Amgen were worth $7,739,000 as of its most recent filing with the Securities & Exchange Commission.
- [By Logan Wallace]
Amgen (NASDAQ:AMGN) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Monday.
- [By Chris Lange]
Amgen Inc. (NASDAQ: AMGN) shares made a slight gain on Tuesday after it was announced that the U.S. Food and Drug Administration (FDA) approved its treatment of glucocorticoid-induced osteoporosis in men and women at high risk of fracture. Specifically, the agency approved Prolia (denosumab), driven by positive late-stage results.
- [By Keith Speights]
It’s not too hard to find biotech stocks that are bargains right now. Two of the most attractively priced biotech stocks on the market are Amgen (NASDAQ:AMGN) and Gilead Sciences (NASDAQ:GILD). Both stocks also provide nice dividend yields for income-seeking investors.
- [By ]
For example, if you buy 100 shares of theNasdaq100ETF(NYSE: QQQ), you’re theoretically buying 11.9 shares of Apple (NASDAQ: AAPL)… 7.7 shares of Facebook (NASDAQ: FB)… 1.8 shares ofAmgen(NASDAQ: AMGN)… 2.6 shares of Comcast (NASDAQ: CMCSA)… and even smaller amounts of about 95 different companies.
Top Biotech Stocks To Watch Right Now: ArQule Inc.(ARQL)
- [By Joseph Griffin]
Shares of ArQule, Inc. (NASDAQ:ARQL) were down 5.4% during trading on Wednesday . The company traded as low as $4.71 and last traded at $4.73. Approximately 3,358,864 shares traded hands during trading, an increase of 289% from the average daily volume of 863,008 shares. The stock had previously closed at $5.00.
- [By Ethan Ryder]
ArQule, Inc. (NASDAQ:ARQL) insider Value Fund L. P. Biotechnology sold 1,035,939 shares of the business’s stock in a transaction dated Wednesday, May 30th. The shares were sold at an average price of $5.00, for a total value of $5,179,695.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
- [By Cory Renauer]
What’s behind these dramatic gains? Read on to find out.
Company Gain in H1 2018 Market Cap
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) 270% $1.19 billion
ArQule, Inc. (NASDAQ:ARQL) 235% $482 million
Endocyte, Inc. (NASDAQ:ECYT) 222% $959 million
Madrigal Pharmaceuticals, Inc.(NASDAQ:MDGL) 205% $3.99 billion
Data source: YCharts.
Top Biotech Stocks To Watch Right Now: Biogen Idec Inc(BIIB)
- [By Brian Orelli]
Data source: Ionis Pharmaceuticals.
What happened with Ionis Pharmaceuticals this quarter?
Revenue increased thanks to $41 million in royalties from Biogen’s (NASDAQ:BIIB) sales of Spinraza, up from just $5 million in the year-ago quarter. Because the tiered royalty rates reset each year, the royalties as a percentage of sales will end up being higher in the quarters to come this year. Despite the higher revenue, earnings turned negative on a GAAP (generally accepted accounting principles) basis: Ionis and Akcea Therapeutics (NASDAQ:AKCA) increased spending in preparation for the launch of Tegsedi for hereditary transthyretin amyloidosis (hATTR), and Waylivra for familial chylomicronemia syndrome, a rare disease that causes the buildup of lipids. Ionis is still the majority owner of Akcea, so its financials are incorporated into Ionis’ financials. The Food and Drug Administration pushed back its goal for making a decision on the marketing application for Tegsedi (the new brand name for inotersen) to Oct. 6, 2018. Ionis provided additional data analysis that the FDA needs additional time to review. In April, Ionis signed another deal with Biogen to develop antisense drugs for neurological disorders. In the deal, Ionis gets $1 billion up front, including an equity investment, in exchange for Biogen having first choice of neurology targets on which to exclusively collaborate with Ionis. Biogen is paying for everything beyond the initial discovery stage, with Ionis eligible for royalties and milestone payments as the drugs advance.
Image source: Getty Images.
- [By Benzinga News Desk]
A distillery in a small Spanish town has claimed it invented the original Coca-Cola (NYSE: KO) recipe and now wants recognition: Link
Initial Jobless Claims For Week Ended May 25 221K vs 225K Economist Estimate, Down From 234K In Prior Week
Personal Income Apr. Up 0.3%, Personal Spending Up 0.6%
The Chicago PMI for May is schedule for release at 9:45 a.m. ET.
The pending home sales index for April will be released at 10:00 a.m. ET.
The Energy Information Administration’s weekly report on natural gas stocks in underground storage is schedule for release at 10:30 a.m. ET.
The Energy Information Administration’s weekly report on petroleum inventories will be released at 11:00 a.m. ET.
Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 12:30 p.m. ET.
Fed Governor Lael Brainard will speak at 1:00 p.m. ET.
Data on money supply for the recent week will be released at 4:30 p.m. ET.
Federal Reserve Bank of Dallas President Robert Kaplan is set to speak at 8:30 p.m. ET.
Canaccord upgrades Biogen (NASDAQ: BIIB) from Hold to Buy
Morgan Stanley upgrades Corning (NYSE: GLW) from Equal-Weight to Overweight
Morgan Stanley downgrades Micron (NASDAQ: MU) from Overweight to Equal-Weight
Cantor downgrades HealthEquity (NASDAQ: HQY) from Overweight to Neutral
This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.
- [By Todd Campbell]
PTC Therapeutics (NASDAQ:PTCT) shares took off after updated data from a trial evaluatingrisdiplam suggested it could mount a stiff challenge toBiogen’s (NASDAQ:BIIB)and Ionis Pharmaceuticals'(NASDAQ:IONS)Spinrazafor the treatment of spinal muscular atrophy (SMA), a rare and life-threatening genetic disease. The data is solid, but a one-and-done SMA treatment is already in late-stage studies at Novartis’ (NYSE:NVS), and that therapy could become available as soon as 2019.
- [By Jim Crumly]
As for individual stocks, Biogen (NASDAQ:BIIB) made headlines with positive results from a trial of an Alzheimer’s drug, and PriceSmart (NASDAQ:PSMT) fell after reporting earnings.
- [By Shannon Jones]
In this week’s episode of Industry Focus: Healthcare, host Michael Douglass and Motley Fool contributor Shannon Jones look at what went wrong with Incyte’s Epacadostat, where the company can go from here, and what this unfortunately means for the immuno-oncology sector on the whole. Then, in more pleasant news, the hosts dive into Novartis’ (NYSE:NVS) newest acquisition of gene therapy company AveXis. Find out what this means for Novartis, why Biogen (NASDAQ:BIIB)might be getting the stink eye from their investors right about now, whether or not Novartis overpaid to tuck this company under their belt, and more.